Diabefarm CF, 30 mg 60 pcs

Diabetes mellitus type 2 Diabetes mellitus type 2 in combination with diet therapy and moderate physical activity when the latter is ineffective.

Indications

Diabetes mellitus type 2 in combination with diet therapy and moderate physical activity when the latter are ineffective.

Pharmacological effect

Pharmacotherapeutic group

Special instructions

Treatment with Diabepharm®MB is carried out in combination with a low-calorie, low-carbohydrate diet.

It is necessary to regularly monitor blood glucose levels on an empty stomach and after meals. In case of surgical interventions or in case of decompensation of diabetes, it is necessary to consider the possibility of using insulin preparations.

Patients should be warned about the increased risk of hypoglycemia when taking ethanol, nonsteroidal anti-inflammatory drugs, and fasting. If you take ethanol, it is also possible to develop disulfiram-like syndrome (abdominal pain, nausea, vomiting, headache).

It is necessary to adjust the dose of the drug in case of physical or emotional stress or changes in diet. Elderly people are especially sensitive to the effects of hypoglycemic drugs; patients who do not receive a balanced diet; weakened patients; patients suffering from pituitary-adrenal insufficiency.

At the beginning of treatment, during dose selection, patients prone to developing hypoglycemia are not recommended to engage in activities that require increased attention and speed of psychomotor reactions.

Active ingredient

Gliclazide

Composition

1 tablet contains:

Pregnancy

Contraindicated during pregnancy. Breastfeeding should be stopped during treatment.

Side Effects

Hypoglycemia (in case of violation of the dosage regimen and inadequate diet): headache, feeling of fatigue, feeling of hunger, sweating, severe weakness, aggressiveness, anxiety, irritability, inattention, inability to concentrate and slow reaction, depression, visual impairment, aphasia, tremor, feeling of helplessness, sensory disturbances, dizziness, loss of self-control, delirium, convulsions, hypersomnia, loss of consciousness, superficial breathing, bradycardia.

From the digestive system: dyspepsia (nausea, diarrhea, feeling of heaviness in the epigastrium); anorexia – severity decreases when taken with food; liver dysfunction (cholestatic jaundice, increased activity of “liver” transaminases).

Hematopoietic disorders: anemia, thrombocytopenia, leukopenia.

Allergic reactions: itching, urticaria, maculopapular rash.

Interaction

The hypoglycemic effect of Diabepharma®MB is enhanced by angiotensin-converting enzyme inhibitors (captopril, enalapril), H2-histamine receptor blockers (cimetidine), antifungal drugs (miconazole, fluconazole), non-steroidal anti-inflammatory drugs (phenylbutazone, indomethacin, diclofenac, azapropazone, oxyphenbutazone), tetracycline, fibrates (clofibrate, bezafibrate), anti-tuberculosis drugs (ethionamide), salicylates, indirect coumarin anticoagulants, anabolic steroids, beta-blockers, cyclophosphamide, chloramphenicol, monoamine oxidase inhibitors, long-acting sulfonamides, fenfluramine, fluoxetine, pentoxifylline, guanethidine, theophylline, drugs that block tubular secretion, reserpine, bromocriptine, disopyramide, pyridoxine, allopurinol, ethanol and ethanol-containing drugs, as well as other hypoglycemic drugs (acarbose, biguanides, insulin).

The hypoglycemic effect of Diabepharma®MB is weakened by barbiturates, glucocorticosteroids, sympathomimetics (epinephrine, clonidine, ritodrine, salbutamol, terbutaline), phenytoin, blockers of “slow” calcium channels, carbonic anhydrase inhibitors (acetazolamide), thiazide diuretics, chlorthalidone, furosemide, triamtarene, asparaginase, baclofen, danazol, diazoxide, isoniazid, morphine, glucagon, rifampicin, thyroid hormones, lithium salts, in high doses – nicotinic acid, chlorpromazine, estrogens and oral contraceptives containing them.

When interacting with ethanol, a disulfiram-like reaction may develop.

Gliclazide increases the risk of ventricular extrasystole while taking cardiac glycosides. Beta-blockers, clonidine, reserpine, guanethidine can mask the clinical manifestations of hypoglycemia.

When used simultaneously with drugs that inhibit bone marrow hematopoiesis, the risk of myelosuppression increases.

Overdose

In case of overdose, hypoglycemia is possible, up to the development of hypoglycemic coma.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Pharmacor Production, Russia